Colorectal Cancer – Unmet Need – Unmet Need – Previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer (US/EU)

The treatment landscape for second- and later-line metastatic colorectal cancer with BRAF or RAS mutations is rapidly changing following the market entry of biomarker-specific combination therapies. The BRAF inhibitor Braftovi, combined with Erbitux, is redefining the treatment of BRAF-mutant disease, while Krazati, targeting the KRAS G12C mutation and paired with Erbitux, represents a significant advance in the treatment of RAS-mutant disease. Established therapies such as Erbitux, Vectibix, Zaltrap, Lonsurf, and bevacizumab remain key players, but intensifying competition continues to shape the market. Given the ongoing demand for more-effective, better-tolerated therapies, drug developers must stay ahead of prescribing trends, pricing shifts, and emerging competitors to successfully navigate this market.

QUESTIONS ANSWERED

• Which key factors drive medical oncologists’ prescribing decisions for previously treated BRAF-mutant or RAS-mutant metastatic colorectal cancer?
• How do targeted therapies such as Braftovi and Krazati compare with other brands on key clinical attributes?
• Where are the biggest gaps in drug treatment, and how can new therapies capitalize on these opportunities?
• What trade-offs are medical oncologists willing to make between clinical benefits, side effects, and cost when choosing second- and third-line treatments?

Markets covered: United States, France, Germany, United Kingdom

Primary research: Survey of 60 U.S. and 30 European medical oncologists fielded in March 2025

Key drugs: Braftovi, Krazati, Erbitux, Vectibix, Zaltrap, Lonsurf, bevacizumab

PRODUCT DESCRIPTION

Unmet Need offers insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities, enabling you to:

• Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
• Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
• Analyze market scenarios for different target product profiles using the TPP Simulator.

KEY FEATURE

Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.